Abstract:Vitiligo is an autoimmune skin disorder resulting in the depigmentation of skin characterised by patches of varying sizes and shapes. A common disorder of pigmentation that affects 0.5%–2% of the global population. Despite its well‐understood autoimmune pathogenesis, the targets for effective cytokine intervention remain unclear. Current first‐line treatments include oral or topical corticosteroids, calcineurin inhibitors and phototherapy. These treatments are limited, have varying efficacies, and are associat… Show more
“…A few reports of vitiligo onset during anti-IL-17 treatment (ixekizumab or secukinumab) were reported, and in none of these cases, the biologic drug was interrupted. 5 , 6 , 7 , 8 …”
Section: Discussionmentioning
confidence: 99%
“…Recently, Lee et al 8 reviewed the literature regarding the use of Janus kinase inhibitors and anti-IL-23 in the treatment of vitiligo.…”
Section: Discussionmentioning
confidence: 99%
“…Regarding the use of anti-IL-23, several studies have reported an increase of IL-23 levels in patients with vitiligo; therefore, the authors concluded that considering the established documentation of IL-23 elevation in patients with vitiligo, targeted treatment should be considered as a potential novel therapy. 8 …”
Section: Discussionmentioning
confidence: 99%
“…IL-23 is an important cytokine in autoimmunity, promoting Th17 cell differentiation and causing an inflammatory response, leading to the production of neutrophils; therefore, the authors concluded that the role of these drugs in the treatment of vitiligo could be considered. 8 …”
“…A few reports of vitiligo onset during anti-IL-17 treatment (ixekizumab or secukinumab) were reported, and in none of these cases, the biologic drug was interrupted. 5 , 6 , 7 , 8 …”
Section: Discussionmentioning
confidence: 99%
“…Recently, Lee et al 8 reviewed the literature regarding the use of Janus kinase inhibitors and anti-IL-23 in the treatment of vitiligo.…”
Section: Discussionmentioning
confidence: 99%
“…Regarding the use of anti-IL-23, several studies have reported an increase of IL-23 levels in patients with vitiligo; therefore, the authors concluded that considering the established documentation of IL-23 elevation in patients with vitiligo, targeted treatment should be considered as a potential novel therapy. 8 …”
Section: Discussionmentioning
confidence: 99%
“…IL-23 is an important cytokine in autoimmunity, promoting Th17 cell differentiation and causing an inflammatory response, leading to the production of neutrophils; therefore, the authors concluded that the role of these drugs in the treatment of vitiligo could be considered. 8 …”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.